Mind Medicine (MindMed) Inc. financial data

Symbol
MNMD on Nasdaq
Industry
Medicinal Chemicals & Botanical Products
Location
One World Trade Center, Suite 8500, New York, NY
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 426 % -20.7%
Debt-to-equity 41.5 % +108%
Return On Equity -71.3 % -28%
Return On Assets -50.4 % -8.48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72.1M shares +81.6%
Common Stock, Shares, Outstanding 72.1M shares +85.7%
Entity Public Float 140M USD -48.5%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 71.9M shares +86.4%
Weighted Average Number of Shares Outstanding, Diluted 75.3M shares +95.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 51.1M USD +16.2%
General and Administrative Expense 39.4M USD +6.58%
Operating Income (Loss) -90.5M USD -11.8%
Net Income (Loss) Attributable to Parent -102M USD -35.5%
Earnings Per Share, Basic -2.25 USD/shares -13.1%
Earnings Per Share, Diluted -2.43 USD/shares -22.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 243M USD +108%
Assets, Current 248M USD +107%
Goodwill 19.9M USD 0%
Other Assets, Noncurrent 534K USD +99.3%
Assets 268M USD +88.7%
Accounts Payable, Current 2.94M USD -65.8%
Accrued Liabilities, Current 8.23M USD -17.3%
Liabilities, Current 41.8M USD +19.2%
Other Liabilities, Noncurrent 15K USD -98.6%
Liabilities 66.1M USD +83%
Accumulated Other Comprehensive Income (Loss), Net of Tax 833K USD +130%
Retained Earnings (Accumulated Deficit) -350M USD -41.1%
Stockholders' Equity Attributable to Parent 202M USD +90.7%
Liabilities and Equity 268M USD +88.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.6M USD -24.5%
Net Cash Provided by (Used in) Financing Activities 169M USD +28930%
Common Stock, Shares, Issued 72.1M shares +85.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 153M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 434K USD
Deferred Tax Assets, Valuation Allowance 51M USD +41.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -102M USD -34%
Deferred Tax Assets, Operating Loss Carryforwards 31.6M USD +24.7%
Unrecognized Tax Benefits 0 USD
Amortization of Intangible Assets 2.1M USD -34.3%
Deferred Tax Assets, Net of Valuation Allowance 114K USD +256%
Share-based Payment Arrangement, Expense 17.6M USD +32.8%
Interest Expense 466K USD +505%